Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
Company profile
Website
CEO
Paul A. Friedman
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
453050834
Latest filings (excl ownership)